gMendel® establishes Board of Directors and announces Appointments
November 15, 2022, Copenhagen – gMendel® announced today its first Board of Directors. The company is also pleased to announce the appointments of Lars Staal Wegner, Chairman, and Hanna Pyokari, Member, to the Board, effective November 1st, 2022. The Board will guide the company forward, especially through shaping public private partnerships, a key factor in unlocking the potential of the gMendel technology for mass screening of genetic disorders.
“We are pleased to welcome Lars Staal Wegner and Hanna Pyokari to the Board. After the successful certification of our technology for Klinefelter syndrome and other chromosomal aberrations, and as we are currently accelerating our efforts to complete the Basic Carrier Test, we have an increased need for strategic guidance from a professional Board of Directors. Both Lars and Hanna bring a strong and diverse mix of expertise to drive gMendel’s mission, including deep industry and regulatory knowledge in healthcare and patient care systems, management and financial expertise to support organic and inorganic growth, and digital innovation leadership”, said Chris Kyriakidis, CEO and co-founder of gMendel.
Lars is an AI-biotech Executive, board member and an active investor in multiple venture funds and start-ups in the medtech, bioinformatics, robotics and fintech sectors. He is also a medical doctor with a passion for fighting cancer, infectious disease and age-related diseases. Throughout his career, he has built, led and grown numerous organisations (How to Robot, Gain and Co, Mypox, Raffle AI, Plex research, PII guard, Recon, formswim, Evaxion Biotech, Bavarian Nordic, Pfizer Denmark) through successful partnerships and commercialisation strategies.
Hanna holds a Master of Science in Economics and Business Administration from Helsinki School of Economics and a CEMS master’s in International Management. She also studied at the Vienna School of Economics. During her 20+ years of career, she has gained international experience in the pharmaceutical industry, including in general management in consumer goods, and most recently in an internal organization within the UN system, where she is heading financial planning and budgeting.
Download the full press release here.
15 Nov 2022gMendel® announced today its first Board of Directors and appointments of Lars Staal Wegner, Chairman, and Hanna Pyokari, Member, effective November 1st, 2022.
27 Sep 2022gMendel® moves into an investment agreement with Polish biotech company genXone for further cooperation in diagnosis of genetic disorders.
29 Aug 2022gMendel® will join TechBBQ on 14 and 15 September to showcase its breakthrough technology for the diagnosis of genetic disorders.
11 May 2022Denmark's vision to become a front-runner in the use of artificial intelligence reflects on the country's national strategy for AI.